Aviva’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$41.6M Buy
459,623
+20,762
+5% +$1.74M 0.06% 276
2026
Q1
$35.1M Sell
438,861
-51,838
-11% -$4.27M 0.06% 290
2025
Q4
$41.8M Buy
490,699
+25,427
+5% +$2.09M 0.07% 253
2025
Q3
$36.2M Buy
465,272
+27,630
+6% +$2.16M 0.07% 272
2025
Q2
$34.2M Sell
437,642
-468,645
-52% -$35M 0.07% 260
2025
Q1
$65.7M Buy
906,287
+108,372
+14% +$7.76M 0.16% 141
2024
Q4
$59.1M Buy
797,915
+20,073
+3% +$1.4M 0.15% 138
2024
Q3
$51.3M Buy
777,842
+212,495
+38% +$15.4M 0.13% 183
2024
Q2
$52.2M Buy
565,347
+173,003
+44% +$15.3M 0.14% 145
2024
Q1
$37.5M Sell
392,344
-102,590
-21% -$8.62M 0.12% 199
2023
Q4
$37.7M Buy
494,934
+61,951
+14% +$4.31M 0.14% 171
2023
Q3
$30M Buy
432,983
+19,992
+5% +$1.61M 0.13% 189
2023
Q2
$39M Sell
412,991
-6,634
-2% -$577K 0.16% 127
2023
Q1
$34.7M Buy
419,625
+70,129
+20% +$5.51M 0.16% 165
2022
Q4
$26.1M Buy
349,496
+54,585
+19% +$4.21M 0.13% 212
2022
Q3
$24.4M Sell
294,911
-800
-0.3% -$77K 0.14% 185
2022
Q2
$28.1M Buy
295,711
+13,343
+5% +$1.38M 0.15% 156
2022
Q1
$33.2M Sell
282,368
-404,882
-59% -$45.4M 0.17% 122
2021
Q4
$89M Sell
687,250
-53,096
-7% -$6.19M 0.37% 52
2021
Q3
$83.8M Buy
740,346
+21,052
+3% +$2.4M 0.37% 54
2021
Q2
$74.5M Buy
719,294
+14,181
+2% +$1.34M 0.33% 67
2021
Q1
$59M Buy
705,113
+343
+0% +$29K 0.29% 82
2020
Q4
$64.3M Buy
704,770
+21,086
+3% +$1.75M 0.33% 68
2020
Q3
$54.6M Buy
683,684
+9,581
+1% +$748K 0.32% 73
2020
Q2
$46.6M Buy
674,103
+3,258
+0.5% +$232K 0.29% 81
2020
Q1
$42.2M Buy
670,845
+114,864
+21% +$8.28M 0.31% 73
2019
Q4
$43.2M Sell
555,981
-45,141
-8% -$3.52M 0.26% 84
2019
Q3
$44.1M Buy
601,122
+242,616
+68% +$17M 0.3% 79
2019
Q2
$22.1M Sell
358,506
-5,994
-2% -$362K 0.15% 142
2019
Q1
$23.2M Sell
364,500
-168,996
-32% -$9.64M 0.16% 137
2018
Q4
$27.2M Sell
533,496
-56,988
-10% -$2.88M 0.2% 109
2018
Q3
$34.3M Sell
590,484
-22,485
-4% -$1.1M 0.19% 121
2018
Q2
$29.7M Sell
612,969
-7,785
-1% -$363K 0.18% 131
2018
Q1
$28.9M Sell
620,754
-32,868
-5% -$1.43M 0.18% 128
2017
Q4
$24.6M Sell
653,622
-37,893
-5% -$1.39M 0.14% 166
2017
Q3
$25.2M Buy
691,515
+11,088
+2% +$423K 0.14% 173
2017
Q2
$26.8M Buy
680,427
+4,860
+0.7% +$177K 0.15% 158
2017
Q1
$21.2M Sell
675,567
-20,790
-3% -$651K 0.12% 184
2016
Q4
$21.8M Buy
696,357
+304,062
+78% +$9.85M 0.13% 179
2016
Q3
$15.8M Buy
392,295
+8,727
+2% +$329K 0.1% 241
2016
Q2
$12.8M Buy
383,568
+55,293
+17% +$1.89M 0.09% 262
2016
Q1
$9.65M Buy
328,275
+5,001
+2% +$138K 0.07% 303
2015
Q4
$8.51M Sell
323,274
-1,146
-0.4% -$29.8K 0.06% 327
2015
Q3
$7.69M Sell
324,420
-82,476
-20% -$1.99M 0.06% 333
2015
Q2
$9.66M Sell
406,896
-20,358
-5% -$459K 0.07% 311
2015
Q1
$10.1M Buy
427,254
+6
+0% +$135 0.07% 326
2014
Q4
$9.07M Buy
427,248
+5,442
+1% +$109K 0.07% 319
2014
Q3
$7.18M Sell
421,806
-5,412
-1% -$85.4K 0.06% 376
2014
Q2
$6.11M Sell
427,218
-2,958
-0.7% -$40.1K 0.05% 438
2014
Q1
$5.32M Sell
430,176
-37,056
-8% -$428K 0.04% 447
2013
Q4
$5.12M Buy
467,232
+10,338
+2% +$117K 0.04% 446
2013
Q3
$5.3M Buy
456,894
+64,512
+16% +$755K 0.05% 396
2013
Q2
$4.39M Buy
+392,382
New +$4.64M 0.04% 388

Other funds holding EW

Aviva's EW Position: Q2 2026 in Review

Aviva increased its Edwards Lifesciences (EW) stake by 4.7% in Q2 2026, buying an estimated $1.74M and bringing the position to 459,623 shares worth $41.6M. The position accounts for 0.06% of the portfolio, ranked #276.

Aviva first reported a position in EW in Q2 2013 and has held it in 53 quarters since. The position peaked at $89M in Q4 2021. 1,325 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Aviva held 459,623 shares of Edwards Lifesciences worth $41.6M as of Q2 2026.
  • Aviva bought 20,762 Edwards Lifesciences shares in Q2 2026, an estimated $1.74M.
  • Edwards Lifesciences made up 0.06% of Aviva's portfolio in Q2 2026, its #276 holding.
  • Aviva first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 53 quarters since.
  • Aviva's Edwards Lifesciences position peaked at $89M in Q4 2021.
  • 1,325 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Aviva's 13F filing for Q2 2026, filed 13 Aug 2026.